Forschungsprojekte
Ergebnisse pro Seite:
100
2021 - 2024
EU ERA PerMed Personalized Medicine- PD Dr. ErnestoBockamp,
- Univ.-Prof. Dr. Dr. DetlefSchuppan
2018 - 2021
“Development of standardized assays for the determination of the activity of amylase-tyrpsin inhibitors in flours and baked products”.- Univ.-Prof. Dr. Dr. DetlefSchuppan
2018 - 2019
“Evaluation of the anti-fibrotic effects of Icosabutate in experimental panlobular liver fibrosis”- Univ.-Prof. Dr. Dr. DetlefSchuppan
2018 - 2021
FEI: “Development of standardized assays for the determination of the activity of amylase-tyrpsin inhibitors in flours and baked products”- Univ.-Prof. Dr. Dr. DetlefSchuppan
2018 - 2021
SFB 1292: “Characterization and modulation of innate myeloid cells in hepatocellular carcinoma”- Prof. Dr. Dr. DetlefSchuppan
2018 - 2021
“Characterization and modulation of innate myeloid cells in hepatocellular carcinoma”.- Univ.-Prof. Dr. Dr. DetlefSchuppan,
- PD Dr. MartinSprinzl
2018 - 2021
Evaluation of the anti-fibrotic effects of Icosabutate in experimental panlobular liver fibrosis- Univ.-Prof. Dr. Dr. DetlefSchuppan
2017 - 2020
Funktionelle Konsequenzen der veränderten Darmflora durch Aufnahme von Gluten und Weizen-aöpha-Amylase-Trypsin-Inhibitoren- Prof. Dr. Dr. DetlefSchuppan
2017 - 2020
Functional consequences of intestinal microbiota altered by ingestion of gluten and wheat alpha-amylase-trypsin inhibitors- Univ.-Prof. Dr. Dr. DetlefSchuppan
2017 - 2018
Evaluation of the anti-fibrotic effect of anti-fibrotic compounds in experimental biliary liver fibrosis- Univ.-Prof. Dr. Dr. DetlefSchuppan
2017 - 2020
Modulation of allergen-induced lung and gut inflammation by nutritional wheat amylase trypsin inhibitors (ATIs), activators of the innate immune system- Univ.-Prof. Dr. Dr. DetlefSchuppan,
- PD Dr. IrisBellinghausen
2017 - 2021
CRC 1066/2: Nanodimensional polymer therapeutics for tumor therapy. "Therapy of metastatic melanoma by addressing tolerance inducing M2-macrophages with therapeutic nanoparticles"- Univ.-Prof. Dr. Dr. DetlefSchuppan,
- PD Dr. AndreaTüttenberg
2017 - 2021
SFB 1066/2: “Therapy of Metastatic Melanoma by Addressing Tolerance Inducing M2-Macrophages with therapeutic Nanoparticles”.- Prof. Dr. Dr. DetlefSchuppan
2017 - 2022
“Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS)”.- Univ.-Prof. Dr. Dr. DetlefSchuppan,
- PD Dr. JörnSchattenberg
2017 - 2020
SPP 1656: “Functional consequences of intestinal microbiota altered by ingestion of gluten and wheat alpha-amylase-trypsin inhibitors”.- Prof. Dr. Dr. DetlefSchuppan
2016
Impact of dietary factors on the gut-CNS-axis - implication for CNS autoimmunity- Univ.-Prof. Dr. Dr. DetlefSchuppan
2016 - 2018
Enzymatic Inactivation of Amylase/Trypsin Inhibitors from Wheat- Univ.-Prof. Dr. Dr. DetlefSchuppan
2016 - 2019
Functional consequences of intestinal microbiota altered by ingestion of gluten and wheat alpha-amylase-trypsin inhibitors- Dr. GeethanjaliPickert
2016 - 2017
Evaluation on the modified fatty acid SEFA 3002 as treatment for the inflammatory and fibrotic pathologies of nonalcoholic steatohepatitis in two complementary optimize mouse models- Univ.-Prof. Dr. Dr. DetlefSchuppan
2016 - 2019
Wheat sensitivity: Impact of wheat varieties and growing conditions on innate immunity- Univ.-Prof. Dr. Dr. DetefSchuppan,
- Prof. Dr. StefanTenzer
2016 - 2019
WHEATSCAN – Identify the causes of wheat Intolerances- Univ.-Prof. Dr. Dr. DetlefSchuppan
2016 - 2019
Human ex vivo model to study nonalcoholic fatty liver disease and its associated pathologies- Univ.-Prof. Dr. Dr. DetlefSchuppan
2016 - 2020
Impact of dietary factors on the gut-CNS-axis – implication for CNS autoimmunity- Univ.-Prof. Dr. Dr. DetlefSchuppan
2016 - 2020
SFB TR 128/2: “Impact of dietary factors on the gut-CNS-axis – implication for CNS autoimmunity”- Univ.-Prof. Dr. Dr. DetlefSchuppan
2015 - 2016
Consideration the amylase trypsin inhibitors (ATI) in wheat cultivation- Univ.-Prof. Dr. Dr. DetlefSchuppan
2015 - 2017
Characterization and modulation of Th17 cells and innate lymphoid cells type 3 in hepatocellular carcinoma- Univ.-Prof. Dr. Dr. DetlefSchuppan
2015 - 2019
Transregio 156 (Heidelberg-Tübingen-Mainz) The skin as sensor and effector organ- Univ.-Prof. Dr. KerstinSteinbrink,
- Prof. Dr. Dr. DetlefSchuppan
2015 - 2017
CI3 Cluster for Individualized Immune Intervention: “Clinical Development of Transglutaminase-Inhibitors for the Treatment of Celiac Disease” (phase 2)- Univ.-Prof. Dr. DetlefSchuppan
2014 - 2017
Use of human and animal tissue slices for the development of anti-fibritic compounds- Univ.-Prof. Dr. Dr. DetlefSchuppan
2013 - 2017
Therapy of Metastatic Melanoma by Adressing Tolerance Inducing Macrophages- PD Dr. AndreaTüttenberg,
- Univ.-Prof. Dr. Dr. DetlefSchuppan
2013 - 2015
Evaluation of the anti-fibrotic effect of three anti-fibrotic compounds in experimental biliary and panlobular liver fibrosis- Univ.-Prof. Dr. Dr. DetlefSchuppan
2013 - 2015
Development of Serum Markers for the Assessment of Liver Fibrosis Progression and Reversal- Univ.-Prof. Dr. Dr. DetlefSchuppan
2013
Therapy of Metastatic Melanoma by Adressing Tolerance Inducing Macrophages- Univ.-Prof. Dr. Dr. DetlefSchuppan
2012 - 2017
Quantitative Imaging of Liver Fibrosis and Fibrogenesis- Univ.-Prof. Dr. Dr. DetlefSchuppan
2012 - 2015
Mechanistic and therapeutic studies for nonalcoholic steatohepatitis (NASH)- Univ.-Prof. Dr. Dr. DetlefSchuppan
2012 - 2015
CI3 Cluster for Individualized Immune Intervention: “Clinical Development of Transglutaminase-Inhibitors for the Treatment of Celiac Disease”- Univ.-Prof. Dr. Dr. DetlefSchuppan
2012 - 2015
Entwicklung von Serummarkern der Progression und Regression der Leberfibrose (BMBF)- Univ.-Prof. Dr. Dr. DetlefSchuppan